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 Summary
	 Background:  Breast	MR	examination	 is	capable	of	detecting	suspected	 lesions	 that	are	not	visualized	by	other	
imaging	techniques,	such	as	mammography	or	ultrasonography.	In	all	cases	such	lesions	should	be	
verified	histopathologically	by	MR-guided	core	biopsy.
	 	 The	aim	of	 the	 study	was	 the	determination	of	 effectiveness	of	MR-guided	breast	 core	biopsy	 in	
detection	of	breast	pathologies.
 Material/Methods:  Twelve	women	with	suspected	 lesions	detected	by	MR	 (GEMS	Signa	Excite	1.5	T	with	4-channel	
open	breast	 coil	manufactured	by	MRI	Devices	Corporation)	were	qualified	 to	MR-guided	breast	
biopsy.	 Obtained	 image	 data	were	 transferred	 to	 DYNACAD	workstation	 for	 calibration,	 lesion	
localization,	 and	 automatic	 calculation	 of	 target	 coordinates	 for	MR-guided	 intervention.	Biopsy	
was	performed	using	automated	14G	biopsy	needle.
	 Results:	 MR-guided	breast	biopsy	was	performed	in	9	women	and	confirmed	lobular	and	ductal	carcinoma	
in	 2	 patients	 respectively,	 lobular	 carcinoma	 in	 situ	 (LCIS)	 in	 1,	 intraductal	 papilloma	 in	 2,	 and	
intraductal	hyperplasia	without	atypia.	In	3	patients	histopathologic	examination	revealed	benign	
fibrocystic	lesions.	Three	women	were	disqualified	from	biopsy	because	pre-biopsy	MR	sequences	
did	not	 reveal	 the	 lesion	 in	 1	 case,	 and	due	 to	 the	 target	 localization	 out	 of	 reach	 of	 the	biopsy	
needle	in	other	2	cases.
	 Conclusions:  All	 non-palpable	 lesions	 visualized	 by	MR	 (contrast-enhanced	 signal	 in	 dynamic	 examination)	
should	 be	 verified	 by	MR-guided	 breast	 biopsy.	 In	 each	 case	 histopathologic	 findings	 should	 be	
compared	with	the	pre-biopsy	images	(morphology	and	enhancement	pattern).
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Background
Over	 the	past	 ten	years	breast	MR	examination	proved	 to	
be	 effective	 in	 detecting	 breast	 cancers.	Until	 recently	 it	
has	been	applied	as	a	complimentary	examination	to	mam-
mography	and	US,	but	today	it	often	plays	the	deciding	role	
in	diagnostically	uncertain	cases	[1].	
MR	mammography	 is	 characterized	by	high	 sensitivity	 in	
detection	of	pathological	changes	with	lower	specificity	 in	
diagnosing	neoplastic	lesions	[2].	Due	to	relatively	high	cost	
it	is	not	applied	in	routine	breast	diagnostics.	Today	the	most	
common	 indications	 include:	 shedule	 breast	 conservative	
theraphy	 –	 BCT,	 follow-up	 after	 conservative	 opera-
tion,	 carrier	 state	 of	BRCA1,	BRCA2	 or	CHEK2	 type	 gene	
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	mutation	which	 increase	 the	 risk	 for	 breast	 cancer,	 per-
sistent	hemorrhagic	exudate	from	the	nipple	with	no	cause	
visible	in	other	examinations,	metastases	to	axillary	lymph	
nodes	 of	 unknown	 origin,	 positive	 result	 of	 fine	 needle	
biopsy	or	core	biopsy	of	breast	without	visualization	of	the	
lesion	in	the	following	imaging	examinations	[1,	2,	3].	
A	 common	denominator	 of	 all	 those	 cases	 is	 the	possibil-
ity	 to	 detect	 a	neoplastic	 focus	 invisible	 in	 other	 imaging	
examinations	 of	 breast	 –	 mammography,	 US	 or	 rarely	
	galactography.	However,	 having	 visualized	 the	 suspected	
lesion	 based	 only	 on	 the	MR	 examination,	 it	 is	 extreme-
ly	 difficult	 to	 obtain	 a	 histopathologic	 result	 that	would	
	reliably	define	its	character.	
Therefore	 the	MR	 breast	 examinations	 use	 the	 so-called	
open	 mammographic	 coils	 cooperating	 with	 localization	
devices	(fig.	1,	2)	and	specialist	software	enabling	to	deter-
mine	 location	 of	 the	 lesion	 for	 insertion	 of	 the	 localized	
needle	 (in	order	 to	perform	an	open	surgical	biopsy]	or	 to	
perform	percutaneous	MR-guided	core	biopsy	[2,	4].	
The	aim	of	this	study	is	to	present	self-	experienced	initial	
attempts	to	perform	MR-guided	core	breast	biopsy.
Materials and methods
The	number	 of	 patients	 referred	 to	 breast	magnetic	 reso-
nance	in	whom	only	the	MR	showed	suspected	lesions,	was	
24	 in	total,	mean	age	of	47.	All	of	 them	previously	under-
went	 clinical	 examination,	mammography	 (2	 projections)	
and	US	 (probe	 7.5-12	Mhz)	 but	 none	 of	 the	 examination	
revealed	 focal	 lesions.	 The	 reason	 to	 refer	women	 to	 the	
MR	 examination	was	 a	 scheduled	BCT	 in	 9	women,	 car-
rier	 state	 of	BRCA1	gene	mutation	 in	11	women	and	 in	4	
patients-	a	 follow-up	after	mastectomy.	Hormone	replace-
ment	theraphy	(SHT)	was	taken	by	8	women.	
The	 MR	 showed	 suspected	 lesions	 and	 all	 24	 women	
underwent	 repeated	US	 examination	with	 another	 evalu-
ation	of	previous	mammography	exams.	In	12	of	them	the	
lesions	 presented	 in	MR	were	 visualized.	 Those	women	
were	referred	to	breast	biopsy	guided	by	US	(11	patient)	or	
mammography	(1	patient).
In	another	12	patients	the	repeated	examinations	did	not	
show	lesions	found	in	MR.	Those	patients	were	referred	
to	MR	 guided	 biopsy.	 Finally,	 biopsy	was	 performed	 in	
9	patients.	 The	 shortest	 period	 of	 time	 between	 the	
diagnostic	MR	and	 biopsy	was	 1	week	 and	 the	 longest	
–	1	month.	
The	 diagnostic	 MR	 of	 breast	 was	 performed	 using	
MR	 system	 -	 GEMS	 Signa	 Excite	 1.5	 T	 with	 4-chan-
nel	 open	mammographic	 coil	 produced	 by	MRI	Devices	
Corporation.	 The	 investigations	 were	 conducted	 in	
two	 stages-	 first	 images	were	 taken	 in	 frFSET2,	 FSET1,	
frFSET2+FS	sequences	 in	 transverse	planes	and	 frFSET2	
Figure 1.	 	Breast	MR	coil	A.	Open	breast	coil	allowing	breast	biopsy	only	from	lateral	access	B.	Open	breast	coil	with	immobilization	and	biopsy	
positioning	device.
Figure 2.	 	Breast	biopsy	set	A.	immobilization	with	biopsy	positioning	device	–	pillar	system,	allowing	accurate	needle	guidance,	according	to	already	
calculated	coordinates	(vertical,	horizontal,	depth	and	angulation)	B.	MR-compatible	core	biopsy	kit	12G:	automatic	biopsy	gun,	coaxial	
needle	and	stylet.	
A B
A B
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in	 the	 sagittal	 plane.	 Additionally,	 in	 frontal	 layers	 in	
SE	 T1	 sequence	 for	 assessment	 of	 axillary	 fossa	 before	
contrast	 agent	 administration.	 Afterwards	 a	 dyna-
mic	 MR	 examination	 was	 performed	 in	 3D	 T1	 DYN	
sequence	 with	 6-time	 repetition	 after	 contrast	 injec-
tion	with	 the	 volume	 encompassing	whole	 breasts	 and	
again	 in	 frontal	 planes	 in	 SE	 T1	 sequence	 for	 evalua-
tion	of	axillary	fossa	(table	1).	In	all	cases	we	applied	the	
Multihance	 contrast	 medium	 in	 a	 dose	 of	 0,1	ml/kg	 of	
body	mass.	
After	 each	 examination	 the	 visualized	 focal	 lesions	were	
evaluated	morphologically	 and	 their	 signal	 enhancement	
curves	were	studied	using	the	DynaCAD	software.	
During	 MR	 evaluation,	 the	 following	 parameters	 were	
taken	into	consideration:
1.	Presence	or	lack	of	contrast	enhancement	of	signal	from	
focal	lesion.
2.	Morphokinetics	of	contrast	enhancement:
–		centripetal	(lesion	enhanced	from	periphery	to	the	centre)
–	centrifugal	(lesion	enhanced	from	centre	to	the	periphery)
–	homogenous	(lesion	enhanced	homogenously)
–	heterogeneous	(lesion	enhanced	heterogeneously)
3.		The	level	of	maximum	signal	increase	1-3	minutes	after	
intravenous	 contrast	 medium	 administration	 (early	
phase)
4.		The	level	of	maximum	signal	increase	3-6	minutes	after	
contrast	medium	administration	(late	phase)
5.		The	shape	of	signal	enhancement	curve	in	both	phases	of	
dynamic	imaging.	
6.		The	presence	 or	 lack	of	 contrast	wash-out	 effect	 in	 the	
early	phase	
Table 1.		MR	sequences	with	their	parameters	applied	in	the	examination.
Used	sequenses Parameters
FSE	T2	AX TR:	 4840	 ET:	16
TE:		 83.2
Thk:	 5.0	mm
SP:	 1.0	mm
DFOV:	 32.9x32.9
MATRIX:	 512x512	
FSE	T2	+	FAT	SAT	AX TR:	 4600	 ET:	18
TE:		 84.4
Thk:		 5.0	mm
SP:		 1.0	mm
DFOV:	 32.9x32.9
MATRIX:	 512x512	
FSE	T1	AX TR:	 520	 ET:	4
TE:	 10.3
Thk:	 5.0	mm
SP:	 1.0	mm
DFOV:	 32.9x32.9
MATRIX:	 512x512	
FSE	T2	SAG TR:	 3260	 ET:	18
TE:	 83.2
Thk:	 5.0	mm
SP:	 1.0	mm
DFOV:	 24.0x24.0
MATRIX:	 512x512	
T1	COR	(węzły) TR:	 520.0	 ET:	4
TE:	 10.3
Thk:	 5.0	mm
SP:	 1.0	mm
DFOV:	 37.9x37.9
MATRIX:	 512x512	
3D	T1	DYN	AX TR:	 3.6	 ET:	0
TE:	 1.0
Thk:	 4.0	mm
SP:	 2.0	mm
DFOV:	 33.9x33.9
MATRIX:	 512x512	
Table 2.		BI-RADS	Classification.
0 points 1 point 2 points
Shape of lesion round	or	oval spicular,	irregular	 -
Margins circumscribed ill-defined -
Contrast enhancement homogenous heterogenous rim
Initial contrast enhancement* <	50% 50-100% >	100%
Postinitial contrast enhancement in later phase** continuous plateau wash-out	effect	especially	over	10%
*	early	enhancement	measured	to	3	minutes	after	contrast	agent	administration;	**	measured	after	3	minutes	from	contrast	administration.
Concerning	the	number	of	points	of	each	lesion,	it	was	qualified	to	one	of	the	five	groups:
Group	I:	0	points,	no	lesions	–	routine	examinations	depending	on	age
Group	II:	1-2	points,	benign	lesion	–	routine	examinations	depending	on	age
Group	III:	3	points,	lesion	probably	benign,	next	MR	in	6	months	
Group	IV:	4-5	points,	suspicious	lesion	–	suggested	biopsy
Group	V:	6-8	points,	lesion	highly	suspicious	–	necessary	histopathologic	verification
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Additionally,	every	visualized	lesion	was	assessed	using	the	
BIRADS	 (Breast	 Imaging	Reporting	 and	Data	 System)	 for	
MR	–	table	2.	
We	decided	 that	patients	with	 lesions	visualized	 in	breast	
MR	and	qualified	to	group	IV	or	V	will	be	referred	to	MR-
guided	biopsy.	Additionally,	in	a	few	first	patients	the	biop-
sy	will	be	carried	out	 in	patients	with	 lesions	qualified	to	
group	III.	
The	 biopsy	was	 given	 up	 in	 cases	 of	multiple	 small	 dis-
seminated	areas	of	contrast	enhancement	observed	in	both	
breasts.	
In	 order	 to	perform	a	biopsy	 the	patient	was	 laid	down	 in	
prone	position	in	order	to	place	the	breasts	inside	the	opened	
biopsy	coil.	Then	the	examined	breast	was	put	into	a	special	
pressing	 construction	 with	 measuring-calibrating	 system	
which	enabled	insertion	of	a	needle	in	further	procedure.	
After	a	shortened	version	of	MR	examination	in	3D	T1	DYN	
sequence	 after	 intravenous	 contrast	 agent	 administration	
(Multihance,	 dose-0,1	ml/kg	 of	 body	mass),	 imaging	 data	
were	 transferred	 to	DYNACAD	diagnostic	 station	 for	 cali-
bration	and	localization	of	the	suspected	lesion	with	auto-
matic	calculation	of	the	parameters	for	insertion.	For	biop-
sy,	we	used	needles	with	diameter	of	14G	with	automatic	
biopsy	gun.	
Figure 3.	 	MR	examination	of	the	right	breast	A.	image	of	the	right	breast	in	FSE	T2	sequence	B.	right	breast	in	dynamic	3D	T1	sequence	–	image	of	
the	suspected	lesion	2	minutes	after	contrast	infusion	–	arrow.
Figure 4.	 	MR	examination	of	the	right	breast,	3D	T1	dynamic	sequence	with	contrast	A.	suspected	lesion	of	the	right	breast	–	post-processing	image	
from	Dynacad	workstation;	3D	T1	sequence	with	colour	coded	contrast	enhancement	B.	dynamic	contrast	enhancement	curve	wash-in/
wash-out	type,	calculated	for	suspected	lesion,	wash-out	–	11%.
A B
A
B
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The	 patients	were	 always	 informed	 that	 every	move	 of	
their	 body	 can	 result	 in	 failure	 of	 the	 procedure	 due	 to	
dislocation	 of	 the	 lesion	 from	 to	 the	 previously	 calcu-
lated	 parameters.	 Before	 the	 needle	 insertion	 the	 site	
was	 injected	 with	 1%	 lignocaine.	 In	 total,	 5	 samples	
were	collected	as	the	needle	position	was	changed	(clock	
hours	were	the	reference	points)	from	12	o’clock,	through	
3,	 6,	 9	 to	 12	 once	 again.	 Marker	 was	 not	 put	 on	 the	
biopsy	site.	
The	 procedure	was	 performed	with	 the	 table	 set	 on	 the	
so-called	 „home”	 position,	 in	which	 the	 patient	 is	maxi-
mally	moved	 away	 from	 the	 inside	 of	 permanent	magnet	
but	 the	 system	can	 still	 record	 the	data	 from	 localization	
sequences.	 It	 ensured	 the	possibility	 to	quickly	 repeat	 the	
control	sequence	(depending	on	the	needs	it	can	be	during	
or	right	after	the	biopsy)	without	the	necessity	of	repeating	
the	 localization	 sequences,	 in	 other	words	 preserving	 the	
continuity	of	a	single	MR	examination	(fig.	3-11).	
After	the	procedure	pressure	dressing	was	applied	with	an	
elastic	bandage.	
The	 material	 was	 put	 in	 10%	 formalin	 and	 sent	 to	 his-
topathologic	examination	to	the	Chair	of	Pathomorphology	
CM,	Jagiellonian	University.	
Figure 5.	 	MR	examination	of	the	right	breast,	3D	T1	dynamic	
sequence	with	contrast	A.	suspected	lesion	of	the	right	
breast	–	post-processing	image	from	Dynacad	workstation;	
3D	T1	sequence	with	colour	coded	contrast	enhancement	
B.	dynamic	contrast	enhancement	curve	wash-in/wash-out	
type,	calculated	for	suspected	lesion,	wash-out	–	11%.
Figure 6.	 	Pre-biopsy	localization	procedure	A.	suspected	lesion	of	the	right	breast	–	post-processing	image	from	Dynacad	workstation,	3D	T1	
sequence	with	colour	coded	contrast	enhancement;	marking	the	lesion	with	blue	cross	results	in	automatic	calculation	of	biopsy	target	
parameters,	green	line	showing	the	distance	the	needle	needs	to	cover	to	get	to	the	target	B.	Schema	of	the	immobilization	and	biopsy	
positioning	device	with	already	adjust	position	to	biopsy,	based	on	the	calculated	target	parameters	(left,	lower	corner	of	the	image).
A B
A
B
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Results
Twelve	women	were	referred	to	MR-guided	biopsy.	
In	 one	woman	 after	 dynamic	MR	of	 breast	 performed	 in	
order	 to	 localize	 the	 lesion,	 no	 signal	 enhancement	was	
observed	 around	 the	 lesion	 qualified	 for	 biopsy	 based	 on	
the	previous	diagnostic	MR	of	breast.	The	next	MR	carried	
out	instantly,	this	time	without	pressure,	did	not	show	the	
lesion	 described	 in	 the	 previous	MR	 exam	 either.	 As	 the	
lesion	was	neither	 visualized	 in	MR	performed	6	months	
later,	it	was	considered	to	be	an	artifact.	
Figure 7.	 	Control	images	of	the	breast	during	and	after	biopsy	
A.	suspected	lesion	in	dynamic	3D	T1	FS	sequence	before	
biopsy,	with	biopsy	needle	right	in	front	of	the	lesion,	after	
releasing	the	spring-loaded	needle	it	moves	forward	1	cm	
hitting	the	lesion.	B.	suspected	lesion	in	dynamic	3D	T1	
sequence	just	after	biopsy;	part	of	the	lesion	disappears.
Figure 8.	 	MR	examination	of	the	left	breast	A.	image	of	the	left	breast	
in	dynamic	3D	T1	sequence	with	contrast	infusion,	axial	
plane	B.	image	of	the	left	breast	in	FSE	T2	sequence,	
sagittal	plane	C.	image	of	the	left	breast	in	FSE	T2	
sequence	with	suspected	lesion	marked	with	blue	cross,	
sagittal	plane.
A B
A B
C
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In	 2	women	 the	 lesion	 qualified	 for	 biopsy	was	 located	
in	 the	upper	 inner	 quadrant,	 close	 to	 the	 thoracic	wall-	
beyond	 the	 reach	 of	 biopsy	 needle.	 In	 follow-up	MR	 of	
breast	 repeated	 after	 6	 months	 the	 image	 of	 described	
areas	remained	unchanged.	Due	to	the	fact	that	they	were	
initially	 qualified	 to	 group	 III	 according	 to	BIRADS,	 the	
following	MR	was	scheduled	to	be	performed	in	6	months	
time	 and	 systematic	 conventional	 imaging	 examinations	
were	recommended	as	well.	
In	 all	 9	 women	 who	 underwent	 the	 procedure	 the	
obtained	 material	 was	 sufficient	 for	 histopathologic	
investigation.	In	3	cases	neoplastic	lesions	were	revealed	
–	 1	 ductal	 carcinoma,	 1	 lobular	 carcinoma,	 1	 lobu-
lar	 carcinoma	 in	 situ	 (LCIS),	 in	 2	 patients-	 intraductal	
	papilloma,	 in	 1–	 intraductal	 hyperplasia	without	 atypia	
and	in	the	remaining	3	–	benign	degenerative	fibrocystic	
lesions.	
None	of	the	patients	suffered	from	side	effects.	In	3	of	them	
mild	 livid	 coloration	 appeared	 on	 skin	 but	 disappeared	
spontaneously.	 Follow-up	 US	 examinations	 carried	 out	
7	days	later	showed	nothing	more	than	a	little	distortion	of	
tissue	at	biopsy	site.	
A B
Figure 9.	 	MR	examination	of	the	left	breast,	3D	T1	dynamic	
sequence	with	contrast	A.	suspected	lesion	of	the	left	
breast	–	post-processing	image	from	Dynacad	workstation;	
3D	T1	sequence	with	colour	coded	contrast	enhancement	
B.	dynamic	contrast	enhancement	curve	wash-in/wash-out	
type,	calculated	for	suspected	lesion,	wash-out	–	25%.
Figure 10.	 	Pre-biopsy	localization	procedure	A.	suspected	lesion	
of	the	left	breast	–	post-processing	image	from	Dynacad	
workstation;	3D	T1	sequence	with	colour	coded	contrast	
enhancement,	marking	the	lesion	with	blue	cross	results	
in	automatic	calculation	of	biopsy	target	parameters,	green	
line	showing	the	distance	the	needle	needs	to	cover	to	get	
to	the	target	B.	Schema	of	the	immobilization	and	biopsy	
positioning	device	with	position	already	adjusted	to	biopsy,	
based	on	the	calculated	target	parameters	(left,	lower	
corner	of	the	image).
A B
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Patients	with	neoplastic	lesions	in	breasts	were	referred	to	
surgical	procedures.	In	2	cases	postsurgical	histopathologic	
examinations	 confirmed	 the	biopsy	 findings	and	 in	1	 case	
the	biopsy	diagnosis	was	changed	 (based	on	postoperative	
finding)	 from	LCIS	 to	 invasive	 lobular	 carcinoma.	For	 the	
results-	see	Table	3.	
Discussion
Open	 surgical	 biopsies	 or	 US	 and	 mammography-guided	
core	 biopsies	 are	 the	most	 commonly	 applied	 procedures	
as	 they	 can	 verify	 the	 character	 of	 nonpalpable	 lesions.	
Relative	 simplicity	 and	possibility	 of	 its	 fast	 performance	
explains	why	 they	 are	 preferred	 in	 all	 cases	where	 it	 is	
possible	to	visualize	suspected	lesions	using	the	aforemen-
tioned	methods.	Indeed,	in	12	cases	that	we	studied	presen-
tation	of	the	suspected	lesions	in	MR	examination	enabled	
visualization	of	the	lesions	in	repeated	conventional	exams	
and	then	performance	of	biopsy	with	guidance	of	the	afore-
mentioned	techniques.
At	 the	 same	 time	 the	MR	examination	 of	 breast	 becomes	
more	and	more	popular	and	visualization	of	 lesions	unde-
tectable	 in	 other	 imaging	 examinations	 has	 become	 the	
reason	 for	 introduction	 of	 similar	 verifying	methods	 per-
formed	with	MR	guidance.	
The	 method	 first	 developed	 was	 the	 MR-guided	 inser-
tion	 of	 localization	needles	with	 a	 following	 open	 surgi-
cal	 biopsy.	 Considering	 the	 logistics	 (significant	 distance	
from	operating	suite,	necessity	to	precisely	coordinate	the	
work	 at	MR	 laboratory	with	 surgical	 team,	 etc.)	 and	no	
possibility	 of	 follow-up	MR	 examination	 of	 the	 resected	
sample	 to	 investigate	 the	 completion	 of	 procedure	 led	 to	
the	 introduction	 of	 percutaneous	 systems	 for	MR-guided	
core	biopsies	[5].
Table 3.		Number,	localization,	morphology	and	comparison	of	histopathologic	post-biopsy	results	(MR	guided)	with	histopathology	after	
surgical	excision.
Patient 
No. Lesion localization Dimensions 
Group according 
to BIRADS Post-biopsy histopathology
Postsurgical 
histopathology
1. RB,	marginal	outer	qw. 	8x10	mm III Fibroadipose	tissue.	in	lymph	gland,	
(mild	dysplasia)
Not	performed
2. RB,	marginal	upper	qw. 8x10	mm V Ca	lobulare;	ADH Ca	lobulare;	Ca	ductale
3. LB,	upper	inner	qw. 10x5	mm III Fibrous	tissue	(mild	dysplasia) Not	performed
4. RB,	lower	outer	qw. 6x7	mm III Fibroadipose	tissue	(mild	dysplasia) Not	performed
5. LB,	lower	outer	qw 7x10	mm IV ca	ductale ca	ductale
6. RB,	marginal	outer	qw. 10x6	mm IV Fibrous	tissue,	dilatated
lactiferous	duct	(mild	dysplasia)
Not	performed
7. RB,	upper	outer	qw. 8x6	mm IV LCIS LCIS,	ca	lobulare
8. RB,	margin	of	outer	qw. 11x10	mm IV papillomatosis	intraductalis Not	performed
9. LB,	upper	outer	qw. 7x8	mm IV NADH Not	performed
Figure 11.	 	Control	images	of	the	breast	during	and	after	biopsy	
A.	suspected	lesion	in	dynamic	3D	T1	sequence	before	
biopsy,	with	biopsy	needle	just	in	front	of	the	lesion,	after	
releasing	the	spring-loaded	needle	it	moves	forward	1	cm	
hitting	the	lesion.	B.	suspected	lesion	in	dynamic	3D	T1	
sequence	just	after	biopsy,	part	of	the	lesion	disappears.
A B
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However,	 problems	and	 limitations	 occurred	 right	 away.	
The	 necessity	 to	 have	 biopsy	 attachment,	 software	 and	
special	open	mammographic	coil	which	gives	access	to	the	
examined	breast	with	no	need	to	move	the	patient	outside	
the	magnetic	 field	 during	procedure,	 became	 fundamen-
tal.	It	was	also	complicated	by	the	fact	that	the	exams	had	
to	 be	 performed	with	 high-field	 devices	 (≥1T)	 of	 closed	
construction	what	 hindered	 the	 access	 to	 the	 examined	
breast.	The	only	 reasonable	 solution	was	pulling	out	 the	
table	with	patient	 (after	pre-biopsy	sequences)	 to	 the	so-
called	 “home”	 position	 [6,	 7].	 The	 duration	 of	 diagnostic	
MR	mammography	 is	 up	 to	 30-40	minutes.	Moreover,	 it	
takes	10-20	minutes	 to	process	 the	examination	on	diag-
nostic	 console.	The	 times	are	 similar	 to	 those	mentioned	
in	literature	[8].	
To	 maximally	 limit	 the	 time	 when	 a	 patient	 needs	 to	
remain	 still,	 in	 our	 institute	 the	 diagnostic	MR	of	 breast	
was	excluded	in	biopsy	procedure.	It	 increased	the	cost	of	
examination	–	the	localization	requires	additional	dynamic	
examination	 after	 contrast	 agent	 administration	 prior	 to	
biopsy	 –	 but	 the	 patient’s	 comfort	 and	 chance	 of	 proper	
insertion	 of	 biopsy	needle	 (due	 to	minimization	 of	 biopsy	
time)	has	improved	greatly.	The	whole	procedure	takes	less	
than	20	minutes	from	placing	the	patient	on	the	table	to	the	
control	sequence	after	biopsy.	
Another	 limitation	of	 the	procedure,	mentioned	by	 radio-
logists	performing	MR-guided	biopsy,	was	the	use	of	open	
mammographic	 coil	 (also	 in	 our	 institute)	which	 allowed	
performing	 a	 biopsy	 only	 from	 the	 lateral	 access	 [2,	 8].	
Therefore,	 for	 us	 it	was	 impossible	 to	 perform	biopsy	 in	
2	patients	in	whom	the	lesions	were	located	near	the	tho-
rax,	 in	 upper	 inner	 quadrants.	 Better	 option,	 preferred	
by	most	 authors,	 is	 to	 use	 coils	which	 enable	 to	 set	 the	
compression-	 calibration	 system	 after	 pulling	 the	 other	
breast	up	and	allow	performance	of	the	biopsy	in	the	inner	
quadrants	as	well.	Unfortunately,	such	coil	 is	much	more	
expensive.	
Similar	difficulties	occur	when	lesions	are	located	in	outer	
quadrants	 and	 close	 to	 the	 thoracic	 wall.	 The	 access	 to	
them	is	blocked	by	the	upper	edge	of	pressing	construction.	
The	 problem	 can	 sometimes	 be	 solved	 by	 strongly	 push-
ing	the	breast	 into	the	hole	 in	the	coil,	 thus	automatically	
	moving	the	lesion	away	from	its	edge.	
In	 the	 presented	 group	 there	was	 also	 a	 case	no	 contrast	
enhancement	 of	 the	 focal	 lesion	 during	 the	 pre-biopsy	
dynamic	sequence.	In	literature	it	is	estimated	for	10	%	of	
cases	and	it	is	explained	by	performing	the	first	MR	exam	
in	 a	 wrong	 period	 of	 the	 menstrual	 cycle	 (not	 between	
5-17th	day	of	the	cycle)	or	by	taking	oral	hormone	substitu-
tive	 therapy	 (HRT)	 [3].	 For	 our	 patients	we	 scheduled	 the	
examination	 according	 to	 the	 day	 of	menstrual	 cycle	 and	
we	always	asked	if	they	took	HST.	In	literature	the	lack	of	
enhancement	 is	 sometimes	 associated	with	 stronger	 com-
pression	of	breasts	what	can	lead	to	difficulties	in	contrast	
blood	supply	 to	 the	 lesion	 [9].	 In	our	case	 it	was	excluded	
in	the	following	MR	examinations	of	breast	which	did	not	
reveal	 the	 previously	 described	 lesion	 and	 allowed	 us	 to	
qualify	it	to	the	group	of	artifacts.	
We	need	to	agree	with	authors	who	emphasize	that	a	reli-
able	 control	 during	 and	 after	 the	 biopsy	 can	 be	 difficult	
due	 to	 occurrence	 of	 artifacts	 in	MR	 images	which	 are	
associated	with	 the	presence	 of	 either	needle	 or	 extrava-
sated	 blood	 [8,	 9,	 10].	 The	 obtained	 results	 suggest	 the	
necessity	to	compare	results	obtained	from	histopathologic	
examination	after	biopsy	with	pre-biopsy	BIRADS	category	
of	 the	verified	 lesion.	Although	 the	histopathologic	 result	
suggesting	 benign	 lesion	 for	 a	 focus	 qualified	 to	BIRADS	
3	 seems	 to	 confirm	 the	 diagnosis,	 similar	 results	 for	 a	
lesion	qualified	to	BIRADS	4	or	5	should	induce	to	consider	
tumorectomy.	
Undoubtedly,	 the	 factor	 that	 influences	 the	 reliability	
of	 histopathologic	 results	 is	 the	 volume	 of	 tissue	 col-
lected	during	biopsy,	i.e.	the	type	of	applied	needle.	Most	
examinations	 seem	 to	 confirm	 that	 the	 best	 results	 are	
acquired	 from	 vacuum	 assisted	 core	 biopsy	 [2,	 8,	 9];	
	however,	high	cost	of	the	appropriate	equipment,	as	well	
as	 the	needle	 itself,	 limit	 the	access	to	this	procedure	 in	
Poland.	
In	 our	 laboratory	we	 perform	biopsy	using	 needles	with	
diameter	of	14G,	with	automatic	biopsy	gun.	
The	 obtained	 results	 -3	 neoplasms	 in	 9	 biopsies-	 sug-
gest	 that	 despite	 the	 difficulties	 (concerning	 mainly	
own	experience	which	needs	 to	 be	 gained	when	a	new	
method	is	introduced)	such	procedure	should	be	applied	
more	 often	 in	 patients	 in	whom	 the	 presence	 of	 focal	
lesion	was	only	 found	 in	MR	of	breast.	One	 should	not	
forget	 that	 approx.	 90%	of	 such	 lesions	 are	 benign	 and	
therefore	 the	 use	 of	 open	 surgical	 biopsy-	 an	 alterna-
tive	for	MR	biopsy-	is	an	unnecessary	mutilation	to	the	
patient.	
Conclusions
1.		Suspected	 focal	 lesion	 revealed	 by	 MR	 examination	
and	visible	in	second-look	US	or	mammography	should	
be	 biopsed	 with	 guidance	 of	 one	 of	 these	 two	 last	
methods.	
2.		All	 nonpalpable	 lesions	 found	 only	 in	MR	 examination	
(which	 show	 contrast	 signal	 enhancement	 in	 dynamic	
examination)	 should	 be	 verified	 with	 percutaneous	
MR-guided	biopsy.	
3.		MR-guided	biopsy	should	not	be	performed	on	the	same	
day	as	diagnostic	MR	of	breast.	
4.		The	most	 universal	 coils	 are	 those	which	 allow	biopsy	
also	from	the	medial	access.	
5.		The	breast	 should	not	 be	 compressed	 too	 strongly	but	
well	 stabilized	 in	 order	 to	 avoid	 difficulties	 in	 blood	
supply;	 it	 reduces	 the	 risk	 of	 no	 supply	 in	 contrast	
blood.	
6.		Mild	 histopathologic	 result	 should	 always	 be	 carefully	
compared	with	pre-biopsy	assessment	–	the	BIRADS	clas-
sification.
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